Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Gilead, Galapagos dip on mixed ulcerative colitis data
Filgotinib is already under regulatory review in the US, Europe and Japan as a treatment for rheumatoid arthritis, but Gilead and Galapagos will need to extend the use of the drug ... The two companies have aspirations to launch filgotinib for no fewer
Latest news
-
NIAID launches COVID-19 trial of remdesivir plus olumiant
It is typically used as an anti-inflammatory for the treatment of adults with moderately to severely active rheumatoid arthritis, along with other auto-immune conditions.
-
Regeneron says antibody for COVID-19 could be ready this year
Regeneron is already working with partner Sanofi to try to repurpose their anti-IL-6 antibody Kevzara (sarilumab) – approved to treat rheumatoid arthritis – as a COVID-19 treatment, and specifically for
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
and rheumatoid arthritis drug Olumiant (baricitinib).
-
Sanofi doses first patient in global Kevzara COVID-19 trial
Both Roche and Sanofi/Regeneron’s drugs are already approved for the treatment of rheumatoid arthritis, but have been repurposed after their potential against COVID-19 was first discovered earlier this
-
FDA approves Roche’s Actemra COVID-19 trial
It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with
More from news
Approximately 56 fully matching, plus 434 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... of the JAK family of kinases leads to an aberrant production
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... filgotinib for rheumatoid arthritis.
-
Will biosimilars ever catch on in the US?
So, for example, AbbVie applied for 247 new patents for adalimumab and was granted 132, even though no significant changes had been made to the rheumatoid arthritis drug.
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... Dysfunction in the regulation of the JAK family of molecules is implicated in the aberrant production of
More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
RWE Blog 1: Real-world challenges and real-world data
Studies in other disease areas, including rheumatoid arthritis, diabetes and psoriasis, support the idea that using products in the real world is different to that in clinical studies.
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data. Click here
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several
-
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada.
-
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU &Japan) 2019 report. ... The qualitative interviews will be enhanced with insights generated from pre-interview patient exercises – such as patient diary entries - to
More from PMHub
Approximately 8 fully matching, plus 17 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
